CFTY720D2406: Long-term, prospective, non-interventional, multinational, parallel cohort study monitoring safety in patients with MS recently initiated with fingolimod once daily or treated with another approved disease-modifying therapy
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Fingolimod (Primary) ; Immunosuppressants
- Indications Multiple sclerosis
- Focus Adverse reactions
- 26 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by United Kingdom Clinical Research Network.
- 11 Jul 2013 New trial record